Kava for the treatment of generalized anxiety disorder RCT: Analysis of adverse reactions, liver function, addiction, and sexual effects

Phytotherapy Research

Volumn 27, Issue 11, 2013, Pages 1723-1728

  Sarris, J ^a,b,c   Stough, C ^b,c   Teschke, R ^d   Wahid, Z T ^b,c   Bousman, C A ^a,b,e   Murray, G ^b   Savage, K M ^b,c   Mouatt, P ^f   Ng, C ^a   Schweitzer, I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^c NICM Collaborative Centre for Neurocognition   (Australia)

^d GOETHE UNIVERSITY   (Germany)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f SOUTHERN CROSS UNIVERSITY   (Australia)

Author keywords

anxiety; kava; liver function; Piper methysticum; safety; sexual function

Indexed keywords

CYTOCHROME P450 2D6; KAVA; PLACEBO;

ADDICTION; ADULT; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ARIZONA SEXUAL EXPERIENCE SCALE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; CYP P450 2D6 GENE; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE; GENERALIZED ANXIETY DISORDER; GENETIC POLYMORPHISM; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SEXUAL FUNCTION; SIDE EFFECT; STOMACH DISEASE; WITHDRAWAL SYNDROME;

PIPER METHYSTICUM;

ANXIETY; KAVA; LIVER FUNCTION; PIPER METHYSTICUM; SAFETY; SEXUAL FUNCTION;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAVA; LACTONES; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PHYTOTHERAPY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; YOUNG ADULT;

EID: 84886244381     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4916     Document Type: Article

References (24)

1. Alramadhan E, Hanna MS, Goldstein TA,. 2012. Dietary and botanical anxiolytics. Med Sci Monit 18 (4): RA40-48.
2. Bauer R,. 2003. Relevant Hepatotoxicity Effects of Kava Still need to be Proven. Planta Med 69: 971-972.
3. Beck AT, Epstein N, et al,. 1988. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 56: 893-897.
4. Clouatre DL,. 2004. Kava kava: examining new reports of toxicity. Toxicol Lett 150 (1): 85-96.
5. Coulter D,. 2007. Assessment of the risk of hepatotoxicity with kava products. WHO appointed committee: Geneva.
6. Hamilton M,. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32 (1): 50-55.
7. Knight J,. 2005. Liver function tests: their role in the diagnosis of hepatobiliary diseases. J Infus Nurs 28: 108-117.
8. LaPorte E, Sarris J, Stough C, Scholey A,. 2011. Neurocognitive effects of kava (Piper methysticum): a systematic review. Hum Psychopharmacol 26 (2): 102-111.
9. McGahuey CA, Gelenberg AJ, Laukes CA, et al,. 2000. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26 (1): 25-40.
10. Montgomery SA, Asberg M,. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
11. Pittler MH, Ernst E,. 2003. Kava extract for treating anxiety. Cochrane Database Syst Rev (1): CD003383.
12. Sarris J, Adams J, Wardle JL,. 2009a. Time for a reassessment of Kava in anxiety? Complement Ther Med 17: 121-122.
13. Sarris J, Kavanagh D, Adams J, et al,. 2009b. The Kava Anxiety Depression Spectrum Study (KADSS): A Mixed Methods Clinical Trial using an Aqueous Extract of Piper methysticum. Complement Ther Med 17 (3): 176-178.
14. Sarris J, Kavanagh D, Byrne G, et al,. 2009c. The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 205 (3): 399-407.
15. Sarris J, LaPorte E, Schweitzer I,. 2011a. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry 45 (1): 27-35.
16. Sarris J, Teschke R, Stough C, Scholey A, Schweitzer I,. 2011b. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward? Planta Med 77 (2): 107-110.
17. Sarris J, Ng C, Schweitzer I,. 2012. Omic" Genetic Technologies for Herbal Medicines in Psychiatry. Phytother Res 26 (4): 522-527.
18. Sarris J, Stough C, Bousman CA, et al,. In press. Kava in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study. J Clin Psychopharmacol.
19. Schweitzer I, Maguire K, et al,. 2009. Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry 43 (9): 795-808.
20. Segraves RT,. 2008. Management of hypoactive sexual desire disorder. Adv Psychosom Med 29: 23-32.
21. Teschke R,. 2010. Kava hepatotoxicity-a clinical review. Ann Hepatol 9: 252-265.
22. Teschke R, Genthner A, Wolff A,. 2009. Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J Ethnopharmacol 123 (3): 378-384.
23. Teschke R, Sarris J, Schweitzer I,. 2012. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol 73 (2): 170-174.
24. Zhou SF,. 2009. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48 (12): 761-804.